Are circulating cytokines reliable biomarkers for amyotrophic lateral sclerosis?

39Citations
Citations of this article
107Readers
Mendeley users who have this article in their library.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that has no effective treatment. The lack of any specific biomarker that can help in the diagnosis or prognosis of ALS has made the identification of biomarkers an urgent challenge. Multiple panels have shown alterations in levels of numerous cytokines in ALS, supporting the contribution of neuroinflammation to the progressive motor neuron loss. However, none of them is fully sensitive and specific enough to become a universal biomarker for ALS. This review gathers the numerous circulating cytokines that have been found dysregulated in both ALS animal models and patients. Particularly, it highlights the opposing results found in the literature to date, and points out another potential application of inflammatory cytokines as therapeutic targets.

Cite

CITATION STYLE

APA

Moreno-Martinez, L., Calvo, A. C., Muñoz, M. J., & Osta, R. (2019, June 1). Are circulating cytokines reliable biomarkers for amyotrophic lateral sclerosis? International Journal of Molecular Sciences. MDPI AG. https://doi.org/10.3390/ijms20112759

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free